摘要
阿尔茨海默病 (AD) 是全球最常见和最严重的年龄依赖性神经退行性疾病。尽管有大量研究致力于阐明这种病理学并开发有效药物,但该疾病的多方面性质和复杂性无疑是迄今为止无法治愈的原因。目前使用的药物主要是通过乙酰胆碱酯酶 (AChE) 抑制来补偿神经递质乙酰胆碱的下降,尽管它们只能提供暂时的对症益处,不能阻止 AD 进展。虽然引发 AD 发病和进展的多种因素尚未完全了解,但已经认识到一些病理特征和潜在途径会导致其病理,例如金属稳态失调、蛋白质错误折叠、氧化应激和神经递质缺乏,其中一些相互关联。因此,最近人们对开发多靶点定向配体 (MTDL) 以与 AD 的几个病理靶点同时相互作用产生了广泛的兴趣。在这篇综述中,介绍了一些关于具有多功能的 MTDL 金属螯合剂的最新报告(2016 年至今)。这些化合物能够击中多种 AD 靶点或途径,例如调节特定的生物金属离子(例如 Cu、Fe、Zn)和蛋白质错误折叠(β-淀粉样蛋白和 tau 蛋白)、抗氧化活性和 AChE 抑制。与原始参考化合物相比,对这些杂合体的特性进行了讨论,鉴于 AD 治疗中的有效潜在应用,一些 MTDL 被概述为未来研究的主要化合物。
关键词: 阿尔茨海默病、多靶点药物、生物金属、金属螯合剂、Aβ 聚集、AChE 抑制剂、抗氧化特性、药物重新定位。
Current Medicinal Chemistry
Title:Recent Multi-target Approaches on the Development of Anti- Alzheimer's Agents Integrating Metal Chelation Activity
Volume: 28 Issue: 35
关键词: 阿尔茨海默病、多靶点药物、生物金属、金属螯合剂、Aβ 聚集、AChE 抑制剂、抗氧化特性、药物重新定位。
摘要: Alzheimer´s disease (AD) is the most common and severe age-dependent neurodegenerative disorder worldwide. Notwithstanding the large amount of research dedicated to both the elucidation of this pathology and the development of an effective drug, the multifaceted nature and complexity of the disease are certainly a rationale for the absence of cure so far. Currently available drugs are used, mainly to compensate the decline of the neurotransmitter acetylcholine by acetylcholinesterase (AChE) inhibition, though they only provide temporary symptomatic benefits and cannot stop AD progression. Although the multiple factors that contribute to trigger AD onset and progression are not yet fully understood, several pathological features and underneath pathways have been recognized to contribute to its pathology, such as metal dyshomeostasis, protein misfolding, oxidative stress and neurotransmitter deficiencies, some of them being interconnected. Thus, there is widespread recent interest in the development of multitarget-directed ligands (MTDLs) for simultaneous interaction with several pathological targets of AD. In this review, a selection of the most recent reports (2016-up to present) on metal chelators of MTDLs with multifunctionalities is presented. These compounds enable the hitting of several AD targets or pathways, such as modulation of specific biometal ions (e.g., Cu, Fe, Zn) and of protein misfolding (β-amyloid and tau protein), anti-oxidant activity and AChE inhibition. The properties found for these hybrids are discussed in comparison with the original reference compounds, some MTDLs being outlined as leading compounds for pursuing future studies in view of efficient potential applications in AD therapy.
Export Options
About this article
Cite this article as:
Recent Multi-target Approaches on the Development of Anti- Alzheimer's Agents Integrating Metal Chelation Activity, Current Medicinal Chemistry 2021; 28 (35) . https://dx.doi.org/10.2174/0929867328666210218183032
DOI https://dx.doi.org/10.2174/0929867328666210218183032 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology Telomere Shortening Is a Sole Mechanism of Aging in Mammals
Current Aging Science Spectroscopic Characterization of a Pyridine Alkaloid from an Endophytic Strain of the Fusarium incarnatum-equiseti Species Complex
Current Bioactive Compounds Nasal Delivery of Antioxidants by Cholesterol-incorporated Liposomes Extends the Neuroprotective Time Window in Cerebral Ischemia
Current Pharmaceutical Design HIV-1 gp120 and Drugs of Abuse: Interactions in the Central Nervous System
Current HIV Research Sarcosine-Based Glycine Transporter Type-1 (GlyT-1) Inhibitors Containing Pyridazine Moiety: A Further Search for Drugs with Potential to Influence Schizophrenia Negative Symptoms
Current Pharmaceutical Design Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry The Proteasome in Health and Disease
Current Pharmaceutical Design A Transient Survival Model of Alteration of Electrophysiological Properties Due to Amyloid Beta Toxicity Based on SH-SY5Y Cell Line
Current Alzheimer Research Nifurtimox Hampered the Progression of Astroglioma <i>In vivo Via</i> Manipulating the AKT-GSK3β axis
Current Molecular Medicine Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases
Current Medicinal Chemistry Naturally-occurring Dimers of Flavonoids as Anticarcinogens
Anti-Cancer Agents in Medicinal Chemistry Neuroprotection with Natural Antioxidants and Nutraceuticals in the Context of Brain Cell Degeneration: The Epigenetic Connection
Current Topics in Medicinal Chemistry Insulin Modulates <i>In Vitro Secretion</i> of Cytokines and Cytotoxins by Human Glial Cells
Current Alzheimer Research New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate
Current Medicinal Chemistry Endothelial Cell Targeted Molecular Imaging in Tumor Angiogenesis: Strategies and Current Status
Current Pharmaceutical Biotechnology MiR-340 Reduces the Accumulation of Amyloid-β Through Targeting BACE1 (β-site Amyloid Precursor Protein Cleaving Enzyme 1) in Alzheimer’s Disease
Current Neurovascular Research Novel Therapeutic Approaches Based on the Targeting of Microenvironment-Derived Survival Pathways in Human Cancer: Experimental Models and Translational Issues
Current Pharmaceutical Design KCa3.1 Channels and Glioblastoma: In Vitro Studies
Current Neuropharmacology